A Malvern-based biotech company is making an advantageous acquisition. Baudax Bio will be inheriting an abundance of products following its transaction with Maryland-based TeraImmune. Baudax’s CEO Geri Henwood will continue to lead the newly merged company as CEO, writes John George for the Philadelphia Business Journal.  

The biotech company works on cell therapies to treat rare autoimmune diseases and is developing a neuromuscular blockade program. With the acquisition of TeraImmune, the new company will have T-168 to its clinical resume, which is a cell therapy used to treat multiple sclerosis and organ transplant recipients. T-168 has recently been granted FDA approval for human testing.  

“This combination blends the scientific expertise of the TeraImmune team with the Baudax team’s proven ability to execute clinical development programs, which we believe is a win for the shareholders of both companies,” said Henwood of the unanimous acquisition. 

Read more about Baudax Bio in the Philadelphia Business Journal. 

More about TeraImmune.